Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Bayer heralds pipeline progress, blockbuster launches and advanced flagship products in cell-gene therapy: Our Bureau, Bengaluru Wednesday, April 2, 2025, 14:50 Hrs [IST] Bayer Ph ...
Health plans limit physical or occupational therapy sessions to as few as 20 a year, no matter the patient's infirmities.
"With strongly anchored pipelines, key global partnerships and deliberate plans to navigate regulatory pathways, we believe ...
We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...
The results, published in Cancer Discovery, prime the combination strategy for future clinical ... and RAS therapy for pancreatic cancer," Vonderheide said. "After decades of limited progress ...
The number of people living with depression, anxiety, and eating disorders has grown fast over the last 30 years. Even as ...
1 Psychedelic therapy, once relegated to the ... Placebos are considered the gold standard of clinical trial controls. But, as the FDA notes in the guidance, the use of a traditional placebo ...
Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I am upgrading BEAM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback